Novo Nordisk A/S $NVO Shares Sold by Modera Wealth Management LLC

Modera Wealth Management LLC reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 3.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 331,601 shares of the company’s stock after selling 10,881 shares during the period. Modera Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $12,186,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Revolve Wealth Partners LLC raised its stake in Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after purchasing an additional 200 shares during the last quarter. AQR Capital Management LLC boosted its stake in Novo Nordisk A/S by 21.0% during the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after purchasing an additional 10,758 shares during the last quarter. Sivia Capital Partners LLC boosted its stake in Novo Nordisk A/S by 18.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after purchasing an additional 1,587 shares during the last quarter. Invesco Ltd. boosted its stake in Novo Nordisk A/S by 26.3% during the 2nd quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock worth $28,967,000 after purchasing an additional 87,467 shares during the last quarter. Finally, Gamco Investors INC. ET AL purchased a new stake in shares of Novo Nordisk A/S during the second quarter worth $314,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 2.3%

NYSE NVO opened at $50.29 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The stock has a market capitalization of $224.56 billion, a P/E ratio of 11.81, a PEG ratio of 4.70 and a beta of 0.77. The firm’s 50-day moving average is $46.09 and its two-hundred day moving average is $45.83. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $71.79.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The business had revenue of $10.85 billion during the quarter. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.38 earnings per share for the current year.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: India approved Wegovy for treating MASH, expanding the drug’s potential beyond obesity into fatty liver disease and opening another large growth opportunity. Reuters article
• Positive Sentiment: Novo launched oral Wegovy in Europe after winning European Commission approval, giving it the first GLP-1 pill for weight management in the region and strengthening its first-mover advantage. Yahoo Finance article
• Positive Sentiment: Reuters reported Novo will launch a lower-cost authorized copy of Ozempic in South Africa, a move that could expand access and support volume growth in an important emerging market. Reuters article
• Neutral Sentiment: Analysts at Erste Group trimmed FY2026 EPS estimates slightly to $3.22 from $3.23, a minor cut that does not materially change the current outlook but signals some caution. MarketBeat article
• Neutral Sentiment: Brokerages continue to rate Novo Nordisk around “Hold,” suggesting the recent rally is being met with a more balanced valuation view. American Banking News article
• Negative Sentiment: Some commentary notes that Eli Lilly still has a chance to win parts of the GLP-1 market, highlighting competitive risk even as Novo’s pill gains traction. The Motley Fool article

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Zacks Research cut shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Wolfe Research began coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 26th. They issued a “peer perform” rating on the stock. Finally, Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, May 12th. Five research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.